contact us
sort news by author
Emma Petela, GK Strategy, Jamie Cater, Louise Allen, Robin Grainger,
sort news by category
Insight, Strategy, Impact,
apprenticeships, awards, B2G, Biden, Bills, Blueprint, bolt on, Boris, Boris Johnson, Brexit, business, careers, climate change, clinical trials, commissioning, Communications, Consumer, consumer demands, covid, COVID 19, Crisis comms, culture, d, David Laws, defence, Deregulation, Devolution, Digital, Disruption, diversity, Due Diligence, economic policy, Education, elections, Energy, Energy and Environment, engagement, Environment, Equality, ESG, EU, europe, exit plan, Financial Services, general election, General News, gig economy, GK culture, gk report, Government, government affairs, Health, health & Care Bill, health and care, health and social care, health funding, health insights, Healthcare, Hendy, housing, HS2, i have a voice, infrastructure, insight, insight report, insights, integrated review, internship, Investment, Investor, Investor Backed Businesses, Investor Services, investors, Ioan, Jack Sansum, Jeremy Corbyn, labour conference, Labour market, Legislation, legistation, levy, life sciences, local government, lockdown, medical devices, Medicines, membership bodies, mental health, mental health services, nationalisation, NHS, no, No deal, parliament, pharma, pharmaceuticals, Planning, policy, Political Due Diligence, Politics, Pride Month, Prime Minister, Private Equity, Privatisation, Public Affairs, Public Relations, Public spending, Queen's Speech, rail, recruitment, REF, regulation, sales, Scotland, Scott, Select Committee, select committees, skills, Social Care, Spending Review, Strategic Communications, students, sustainability, Tax, Technology, The Conservative Party, The Labour Party, trade bodies, transformation, Transport, uk, UK Politics, university, US, US election, Wales, Waste, Winter Plan, women, Workplace,
The Medicines and Medical Devices Bill: the impact and opportunity
On the 2nd March 2020, the Medicines and Medical Devices Bill 2019-20 went through its second reading in parliament. It has been one of the first pieces of domestic legislation to be introduced since the Queen’s Speech in December 2019 and represents a critical area of post-Brexit regulatory change. The Bill is politically uncontroversial. It passed first and second readings unopposed by the Labour Party and is more about the need for legislation to return regulatory powers to...
clinical trials , government affairs , Health , Healthcare , life sciences , medical devices , Medicines
Reviewing the draft NHS commercial medicines framework – clarification made possible through collaboration and dialogue
The draft NHS Commercial Framework for Medicines is published and out for consultation. The Framework was a commitment set out in the recent
3 mental health policy issues Boris Johnson’s Government must address
When he’s not testing the rulebook on parliamentary procedure, preparing the country for that inevitable no-deal Brexit, or out on the yet-to-be-declared campaign trail, Boris Johnson likes to tread the line between audacious policy announcements and drafting bullish content for the papers. Back in July Johnson wrote an Op-Ed, citing his hero Winston Churchill and his...
Government , Health , NHS , Healthcare , Education , policy , mental health , mental health services
2 min readEurope and the supply of innovative medicines: why it matters
One of the standout features of the ‘no-deal’ Brexit debate has been the focus on the impact on supplies of medicines and medicinal products. This includes everything from chemical compounds and investigational medicinal products (IMPs) for clinical research through to short shelf-life medicines made on the continent. The debate has been a continuous battle between those outlining the possible impact on patients’ lives while struggling to quantify the extent of the impact. Some areas...
Private Equity investment in Pharma – why is the UK bucking the global trend?
In recent years we’ve become used to claims that the impasse of Brexit is drying up investment in UK life sciences. The argument also goes that global investment by pharmaceuticals in R&D – predicted to grow to $181 billion by 2022 – will instead flow to other countries. There is evidence that can support this theory but if you scrape below the surface and look at investment by private equity into life sciences the picture looks quite different. The figures actually suggest that...
ESG – responsible approaches to vulnerable children
Companies that provide services to children risk losing the trust of children, parents and institutional clients unless they can properly identify and manage vulnerability. Vulnerability is an increasing concern for the investors and companies that GK Strategy advises on ESG (environmental, social and governance) issues. It’s a growing issue for providers of educational, childcare, fostering and healthcare services, as well as residential care and children’s holidays. Vulnerability...